about
High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC studyAssociation between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant dataMendelian randomization of blood lipids for coronary heart disease.Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis.Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators.High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study.The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) studyClinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) studyLarge-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levelsDipeptidyl peptidase IV and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) study.Racial differences in glycemic markers: a cross-sectional analysis of community-based dataA 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study.B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study.Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort.Lactate and risk of incident diabetes in a case-cohort of the atherosclerosis risk in communities (ARIC) study.Total zinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: a 14-cohort meta-analysis.Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities studyThree-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study.Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study.Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels.Plasma lactate and incident hypertension in the atherosclerosis risk in communities studyRole of lipid and lipoprotein profiles in risk assessment and therapy.Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study.High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD.Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities studyPLAC test for identification of individuals at increased risk for coronary heart disease.Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) StudySoluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study.Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy.Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP array.Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD StudyEstimated plasma stearoyl co-A desaturase-1 activity and risk of incident diabetes: the Atherosclerosis Risk in Communities (ARIC) studyNovel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) study.Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence.GCKR and PPP1R3B identified as genome-wide significant loci for plasma lactate: the Atherosclerosis Risk in Communities (ARIC) study.
P50
Q24618394-24E35145-2E43-4222-B86D-6B31B77CE9AAQ28655857-7B3FA597-96C5-4237-982A-CBFC50088D63Q30407506-F8878121-A36A-461A-A829-AD4249BE4507Q30411394-E43958D1-4407-485A-A677-334A35DA9D0CQ30495417-F1913B5C-19C5-4F92-A16B-43EE6245F9F9Q30583705-F8B8B263-F746-428F-9734-33E2DA4F55AAQ30662013-A9471358-E3A6-4B7B-AEC1-0FB3DDD870C8Q33556815-2DC3BFBF-5B98-47F6-9BED-923AAB6D6F8DQ33693760-B689BB41-A54C-4417-9C57-C28F713B17CAQ33773714-846C4DB4-07EC-4F3A-95AE-5CAC34F26F9AQ33804704-8504CDC3-6C5B-4EFE-975A-7DCD57A08BD2Q33831561-40F44595-7222-4F98-B400-272EF1307293Q34237273-2FC4EE38-6A0C-4175-B394-412A92B1CC03Q34342621-3CA73EA0-BA3A-4475-80D0-E359ECF1F8C7Q34354390-6DB8B45B-6D18-40FB-9E28-D749C65BFED7Q34479088-18FA4BDE-E090-4D63-B7B2-FD58EECAC157Q34576075-929D8EE0-9465-440D-B77C-79D0175523E7Q34631381-2C52ECD6-4E0F-48A2-9D52-CA4069B5840AQ34648629-D46066CF-3A4E-42A9-B425-9D71DA15D369Q34679433-1C44359F-7B74-4F39-B09B-A41B2D99A157Q35097016-59195F01-DCBE-4468-9ABF-2FC8FF6D9228Q35102964-3A52AD47-C5BA-4D29-992E-E9F2DD1A6037Q35138365-875B392A-37B5-4D23-B2CA-B4964B93A9BEQ35171809-22EC2CE6-6581-4114-A753-3D850706FEF5Q35188947-2D88FE45-0991-47C9-8B1C-42F710E4353EQ35204621-5AF10A03-0DB5-40DA-9809-0DF039F51063Q35599099-77CEBDA9-DA9D-41ED-8006-F8579847D7E7Q35673148-22BE6EE0-D734-439D-AE00-5B85578B0210Q35881441-E3A52C1C-9F82-4F44-88D7-D43ACC15C225Q36047267-A9B89969-BBC0-4304-A973-2F3A24A97180Q36050527-846DF225-3FB0-4514-8B71-AF906CE95D47Q36143273-B0533E9A-0108-48C9-B384-AEA4183E5029Q36263332-708E165F-F99C-47F2-9AF5-B052B6E27ACCQ36352735-433C1F63-2721-48A3-B258-BA2C6BFCD44DQ36376710-8976390D-0888-4E94-9C87-23A4DF32AEDBQ36387179-3F54EC7C-B8EB-477E-8BBC-E910B7D23E48Q36456941-AEDE0122-BD63-440D-B87D-FE12019910B5Q36477823-228D3513-A954-4F7E-A66D-08E024A0AC90Q36661937-477592E4-3F92-4FA3-9176-F0DC10822630Q36760175-454FBE8C-6525-4881-9ACA-97C01A6634D0
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Ron C Hoogeveen
@ast
Ron C Hoogeveen
@en
Ron C Hoogeveen
@es
Ron C Hoogeveen
@nl
type
label
Ron C Hoogeveen
@ast
Ron C Hoogeveen
@en
Ron C Hoogeveen
@es
Ron C Hoogeveen
@nl
prefLabel
Ron C Hoogeveen
@ast
Ron C Hoogeveen
@en
Ron C Hoogeveen
@es
Ron C Hoogeveen
@nl
P1153
7003459606
P31
P496
0000-0003-2399-4653